Drug intelligence / Profile preview

Flamboyant

Development stage: Unknown
Lead developer: EMS
Modality: Small Molecules
Administration: Inhalation

Overview

Flamboyant (as "Flamboyant 200/12" or "Flamboyant 125/12") is an investigational pharmaceutical drug being developed for the treatment of asthma and potentially various neurological disorders. Clinical development is ongoing in Brazil. The specific composition of the drug (i.e., its active ingredients) has not been disclosed in public sources, but it is being studied as a combination therapy for moderate asthma and other indications.

Brand names: Flamboyant 200/12Flamboyant 125/12
Other names: Flamboyant 125/12budesonide + formoterol EMS

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on Flamboyant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flamboyant.

Explore the full profile